Table 3. Multivariate Cox regression analysis of RFS for different models of SNP rs3775291 and rs4833095.
| Models | HR (95%CI) | P a | |
|---|---|---|---|
| rs3775291: | |||
| Recessive model | <0.01 | ||
| AG+GG | 1.00 | ||
| AA | 3.53 (1.98–6.31) | ||
| Dominant model | 0.34 | ||
| AG+AA | 1.00 | ||
| GG | 0.79 (0.48–1.29) | ||
| Co-dominant model | <0.01 | ||
| GG | 1.00 | ||
| AG | 1.01 (0.59–1.75) | 0.96 | |
| AA | 3.37 (1.74–6.51) | <0.01 | |
| rs4833095: | |||
| Recessive model | 0.08 | ||
| TC+CC | 1.00 | ||
| TT | 0.47 (0.20–1.09) | ||
| Dominant model | 0.19 | ||
| TC+TT | 1.00 | ||
| CC | 1.39 (0.85–2.27) | ||
| Co-dominant model | 0.15 | ||
| CC | 1.00 | ||
| TC | 0.82 (0.50–1.36) | 0.44 | |
| TT | 0.41 (0.17–1.02) | 0.05 | |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor
aAdjusted for lymph node status, tumor size, endocrine therapy, chemotherapy, ER, PR, and HER2 status